This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01625338
First received: June 7, 2012
Last updated: October 9, 2015
Last verified: October 2015
Results First Received: October 9, 2015  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Chronic Hepatitis C
Interventions: Drug: SOF
Drug: RBV
Drug: Peg-IFN

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at a total of 152 study sites from their prior Gilead study in North America, Europe, Australia, and New Zealand. The first participant was screened on 22 June 2012. The last study visit occurred on 22 December 2014.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
585 participants were screened.

Reporting Groups
  Description
SOF+RBV 12 Weeks Sofosbuvir (SOF) 400 mg tablet once daily + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 12 weeks
SOF+RBV 24 Weeks SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks
SOF+RBV+Peg-IFN 12 Weeks SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) + pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly for 12 weeks in participants

Participant Flow:   Overall Study
    SOF+RBV 12 Weeks   SOF+RBV 24 Weeks   SOF+RBV+Peg-IFN 12 Weeks
STARTED   114   200   220 
COMPLETED   82   156   181 
NOT COMPLETED   32   44   39 
Enrolled but not Treated                0                0                1 
Efficacy Failure                27                39                31 
Lost to Follow-up                3                3                2 
Investigator Decision                0                2                1 
Subject Withdrew Consent                1                0                2 
Adverse Event                1                0                1 
Study Discontinued by Sponsor                0                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug.

Reporting Groups
  Description
SOF+RBV 12 Weeks SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks
SOF+RBV 24 Weeks SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 24 weeks
SOF+RBV+Peg-IFN 12 Weeks SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) + Peg-IFN 180 µg administered subcutaneously once weekly for 12 weeks in participants
Total Total of all reporting groups

Baseline Measures
   SOF+RBV 12 Weeks   SOF+RBV 24 Weeks   SOF+RBV+Peg-IFN 12 Weeks   Total 
Overall Participants Analyzed 
[Units: Participants]
 114   200   219   533 
Age 
[Units: Years]
Mean (Standard Deviation)
 53  (9.6)   52  (7.6)   53  (10.0)   53  (9.1) 
Gender 
[Units: Participants]
       
Female   54   50   60   164 
Male   60   150   159   369 
Race/Ethnicity, Customized 
[Units: Participants]
       
White   105   184   187   476 
Black Or African American   4   2   20   26 
Asian   2   6   8   16 
Other   1   3   2   6 
Not Permitted   0   2   2   4 
American Indian Or Alaska Native   2   1   0   3 
Native Hawaiian Or Other Pacific Islander   0   2   0   2 
Race/Ethnicity, Customized 
[Units: Participants]
       
Hispanic or Latino   19   12   20   51 
Not Hispanic or Latino   95   187   197   479 
Not Permitted   0   1   2   3 
Region of Enrollment 
[Units: Participants]
       
United States   77   82   121   280 
United Kingdom   3   10   8   21 
Spain   1   8   2   11 
New Zealand   4   30   6   40 
Canada   7   13   10   30 
Austria   1   2   1   4 
Netherlands   2   4   4   10 
Sweden   2   5   3   10 
Czech Republic   0   0   1   1 
Poland   0   1   8   9 
Italy   3   7   4   14 
Australia   9   14   19   42 
France   2   10   11   23 
Germany   2   12   18   32 
Estonia   1   2   3   6 
HCV Genotype 
[Units: Participants]
       
Genotype 1   0   2   134   136 
Genotype 2   62   10   8   80 
Genotype 3   52   180   74   306 
Genotype 4   0   7   3   10 
Indeterminate   0   1   0   1 
Cirrhosis Status 
[Units: Participants]
       
No   89   138   183   410 
Yes   25   62   36   123 
IL28b Status [1] 
[Units: Participants]
       
CC   38   59   47   144 
CT   61   103   127   291 
TT   13   35   40   88 
Missing   2   3   5   10 
[1] CC, CT, and TT alleles are different forms of the IL28b gene.
HCV RNA 
[Units: Log10 IU/mL]
Mean (Standard Deviation)
 6.3  (0.87)   6.4  (0.70)   6.4  (0.64)   6.4  (0.72) 
HCV RNA Category 
[Units: Participants]
       
< 800,000 IU/mL   30   44   36   110 
≥ 800,000 IU/mL   84   156   183   423 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)   [ Time Frame: Posttreatment Week 12 ]

2.  Primary:   Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event   [ Time Frame: Up to 24 weeks ]

3.  Secondary:   Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)   [ Time Frame: Posttreatment Weeks 4 and 24 ]

4.  Secondary:   Percentage of Participants With On-treatment Virologic Failure   [ Time Frame: Up to 24 weeks ]

5.  Secondary:   Percentage of Participants With Viral Relapse   [ Time Frame: Up to Posttreatment Week 24 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
There were no limitations affecting the analysis or results.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Clinical Trial Disclosures
Organization: Gilead Sciences
e-mail: ClinicalTrialDisclosures@gilead.com



Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01625338     History of Changes
Other Study ID Numbers: GS-US-334-0109
2012-000571-16 ( EudraCT Number )
Study First Received: June 7, 2012
Results First Received: October 9, 2015
Last Updated: October 9, 2015